HepaLife™ Expands Advisory Board to Advance Plans for Bioartificial Liver Clinical Trial

Liver failure experts Dr. Achilles Demetriou, Dr. Fredric Gordon, Dr. Philip Rosenthal, and Dr. John Vierling appointed

Boston, MA - June 02, 2009 - HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing its cell-based bioartificial liver system, HepaMate™, as a potentially lifesaving treatment for liver failure patients, announced the appointment of four additional distinguished liver experts to its Advisory Board to further advance the company's plans for a new clinical trial of its HepaMate™ bioartificial liver system and to refine the clinical strategy and patient treatment protocols.

The Advisory Board is comprised of a total of seven experts, including a Founding Member of the American Society for Diagnostic and Interventional Nephrology, Medical Director of Liver Transplantation at the Lahey Clinic Medical Center in Massachusetts, Director of the MHH Hannover Medical School, Germany, Director of the Bioreactor Group at the University of Pittsburgh’s McGowan Institute for Regenerative Medicine, Director of the Pediatric Liver Transplant Program at the University of California, San Francisco, past Chairman of the Board of the American Liver Foundation, and an initial inventor of the HepaMate™ technology and principal investigator of previous HepaMate™ clinical trials.

As an extracorporeal cell-based bioartificial liver system, HepaMate™ is designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. HepaMate™ is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. These components are assembled into a patented blood/plasma circulation system, which is placed on the HepaDrive™ perfusion platform. There are currently no cell-based liver support systems commercially available or in Phase III clinical trials in the US or Europe.

The HepaMate™ technology has previously been tested in clinical studies involving more than 200 patients. Over 50 scientific papers and book chapters have been published on the technology.

"I am pleased to welcome Dr. Demetriou, Dr. Gordon, Dr. Rosenthal and Dr. Vierling to our team," said Frank Menzler, President and CEO of HepaLife Technologies, Inc. “Recently, we announced plans for a new clinical trial for our HepaMate™ bioartificial liver. The clinical expertise assembled in our Advisory board is extraordinary, not only due to decades of experience in treating patients with liver failure, but also with respect to clinical experience with our own HepaMate™ technology. This will be important for executing an effective and successful clinical study."

Stephen R. Ash, MD, FACP, has been a practicing physician in Internal Medicine and Nephrology at Clarian-Arnett Health in Indiana since 1975. He also is Director of Dialysis at Wellbound, Inc. Dr. Ash is the author of over 30 U.S. patents and over 100 scientific publications. He is Past President of the American Society for Artificial Internal Organs (ASAIO) and a Founding Member of the American Society for Diagnostic and Interventional Nephrology (ASDIN).

Achilles A. Demetriou, MD, PhD, FACS, is President of University Hospitals, a Health System based in Cleveland, Ohio. He is also Professor of Surgery and Vice Dean for Clinical Affairs at the School of Medicine, Case Western Reserve University. Previously, he was Chairman of the Department of Surgery at Cedars-Sinai Medical Center. Dr. Demetriou holds multiple patents in conjunction with his liver research and is co-inventor and developer of HepaLife’s HepaMate™ bioartificial liver technology. Dr. Demetriou was principal investigator and studied 34 liver failure patients with the HepaMate™ technology in previous clinical trials.

Joerg C. Gerlach, MD, PhD, directs the Bioreactor Group at the University of Pittsburgh’s McGowan Institute for Regenerative Medicine, researching stem cell utilization, hybrid organs and bioartificial liver systems. Dr. Gerlach is an internationally renowned authority in liver disease and cutting-edge artificial liver support systems. Dr. Gerlach is a patent-holder in the field, and a published liver expert with more than 100 research publications to his credit.

Fredric D. Gordon, MD, is Medical Director of Liver Transplantation, and Director of Hepatology at the Lahey Clinic Medical Center in Massachusetts. Dr. Gordon has published 130 articles, abstracts and reviews regarding liver transplantation and treatment of hepatic disease. He serves as a reviewer for a number of prestigious journals including JAMA, the New England Journal of Medicine, and the American Journal of Gastroenterology. He is the principle investigator for approximately 10 ongoing studies at the Lahey Clinic.

Michael Ott, MD, PhD, is leading the Cell and Gene Therapy group at the MHH Hannover Medical School, Germany, one of the world's leading centers for the treatment of liver diseases. As an authority in experimental hepatology and highly innovative liver cell transplantation procedures for patients suffering from acute liver failure, Dr. Ott has developed techniques for the isolation, characterization and cryopreservation of human hepatocytes for clinical use according to the guidelines of “current good manufacturing practice” (cGMP).

Philip Rosenthal, MD, is the Director of Pediatric Hepatology, Medical Director of the Pediatric Liver Transplant Program and a Professor of Pediatrics and Surgery at the University of California, San Francisco (UCSF). He is pursuing research on the use of bioartificial liver support and the pharmaceutical treatment of Hepatitis, as well as researching the quality of life following liver transplantation in children. Dr. Rosenthal studied 15 acute liver failure patients with the HepaMate™ technology in a previous clinical trial.

John M. Vierling, MD, FACP, is Professor of Medicine and Surgery, Director of Baylor Liver Health and Chief of Hepatology at the Baylor College of Medicine and Director of Advanced Liver Therapies at St. Luke’s Episcopal Hospital, Texas. Dr. Vierling was President of the American Association for the Study of Liver Diseases and Chairman of the Board of the American Liver Foundation. He has been a member of numerous National Institutes of Health study sections and advisory committees, including the NIDDK Liver Tissue Cell Distribution System. Dr. Vierling previously contributed to the development and clinical application of the HepaMate™ technology by his extensive clinical expertise and by participating in discussions with the US Food and Drug Administration (FDA).

ABOUT HEPALIFE TECHNOLOGIES, INC.

Based in Boston, Massachusetts, HepaLife™ Technologies Inc., is developing its cell-based bioartificial liver system, HepaMate™, as a potentially lifesaving treatment for liver failure patients. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625).

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:
http://www.hepalife.com/investor-alerts.php

To view the full HTML text of this release, please visit:
http://www.hepalife.com/press_releases/20090602.html.php

#      #      #      #

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.